New workers' compensation legislation: expected pharmaceutical cost savings

Area of Science:

• Workers' Compensation Pharmacy Costs
• Healthcare Policy Analysis
• Drug Pricing Systems

Background:

• California's Workers' Compensation (WC) system costs are under review.
• Recent legislation (AB 749, SB 228) necessitates an assessment of pharmaceutical cost savings.
• Evaluating the impact of new pharmacy legislation on WC costs is crucial.

Purpose of the Study:

• To compare pharmaceutical costs and savings in California's Workers' Compensation system before and after new legislation.
• To assess the financial impact of implementing the 100% Medi-Cal fee schedule on WC pharmacy spending.
• To identify potential inconsistencies and long-term implications of the new drug pricing system.

Main Methods:

• Utilized a large workers' compensation database from the California Workers' Compensation Institute (CWCI).
• Incorporated Medi-Cal pharmacy costs from the State Drug Utilization Project.
• Compared 2002 pharmacy data with costs under the new legislation and fee schedule.

Main Results:

• The 100% Medi-Cal fee schedule is projected to yield 29.5% in savings, totaling approximately $125 million.
• Significant variability in savings across different drugs was observed, indicating potential pricing system limitations.
• The new fee schedule resulted in substantial pharmacy cost reductions compared to the former WC fee schedule.

Conclusions:

• While substantial pharmaceutical savings are achievable, inconsistencies between payment systems may create long-term uncertainty.
• Alternative pricing systems and integrated cost-containment strategies, such as pain management, could further optimize drug spending.
• The study highlights the need for careful consideration of pricing system design to ensure sustained cost-effectiveness in WC pharmaceuticals.